Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Regenerx Biopharmaceuticals Inc (RGRX)

Regenerx Biopharmaceuticals Inc (RGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2
  • Shares Outstanding, K 1,509
  • Annual Sales, $ 80 K
  • Annual Income, $ -1,730 K
  • 60-Month Beta 2.57
  • Price/Sales 0.03
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RGRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 01/02/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0012 +16.67%
on 03/20/24
0.0522 -97.32%
on 04/10/24
+0.0002 (+16.67%)
since 03/11/24
3-Month
0.0012 +16.67%
on 03/20/24
0.0522 -97.32%
on 04/10/24
+0.0002 (+16.67%)
since 01/17/24
52-Week
0.0002 +600.00%
on 11/03/23
8.8000 -99.98%
on 05/09/23
-3.4986 (-99.96%)
since 04/17/23

Most Recent Stories

More News
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Receives Stockholder Approval for Reverse Stock Split

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx To Extend Consent Solicitation Vote

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Issues Letter To Stockholders

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Issues 2022 Letter To Stockholders

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

/PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue...

RGRX : 0.0014 (-97.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0014
2nd Resistance Point 0.0014
1st Resistance Point 0.0014
Last Price 0.0014
1st Support Level 0.0014
2nd Support Level 0.0014
3rd Support Level 0.0014

See More

52-Week High 8.8000
Fibonacci 61.8% 5.4385
Fibonacci 50% 4.4001
Fibonacci 38.2% 3.3617
Last Price 0.0014
52-Week Low 0.0002

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar